Microcap Ledger Sanara MedTech Inc. $SMTI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Headquarters
- Fort Worth, TX
- Fiscal year end
- December 31
- Shares outstanding
- 9,188,035 [10-Q 2026-08-11]
What the company doesAI summary of filing
Sanara MedTech is a medical technology company that develops and commercializes surgical products, primarily soft tissue repair and bone fusion products sold to hospitals and surgical centers in the United States. Its main product, CellerateRX Surgical, is a hydrolyzed collagen powder used to manage surgical wounds, while other key offerings include BIASURGE (a surgical irrigation solution), BiFORM (a bone matrix implant), and ALLOCYTE Plus (a cellular bone matrix). The company is revenue-generating, with its products sold directly through field sales representatives and surgical specialty distributors to over 4,000 hospitals as of December 2025. In September 2025, the company discontinued its value-based wound care services initiative (Tissue Health Plus) and shifted focus exclusively to surgical market products. [10-K 2026-03-24]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $55.94M | $6.1K | −$426.9K | $15.42M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $103.12M | $37.56M | $6.79M | $16.58M | [10-K 2026-03-24] |
| FY ended Dec 2024 | $86.67M | $9.66M | −$23.8K | $15.88M | [10-K 2026-03-24] |
- Quarterly cash burn
- −$213.5K
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 8,741,161 | [10-Q 2024-11-12] |
| 2025-03-18 | 8,901,903 | [10-K 2025-03-25] |
| 2025-05-13 | 8,887,853 | [10-Q 2025-05-14] |
| 2025-08-12 | 8,902,351 | [10-Q 2025-08-13] |
| 2025-11-11 | 8,935,657 | [10-Q 2025-11-12] |
| 2026-03-20 | 9,167,040 | [10-K 2026-03-24] |
| 2026-05-08 | 9,163,969 | [10-Q 2026-05-12] |
| 2026-08-07 | 9,188,035 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2024-05-21; declared effective 2024-05-31 [S-3 2024-05-21]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Yon Seth D | other | 3,661 | $35.11 | [4 2026-09-16] |
| 2026-06-04 | Salamone Ann Beal | grant | 4,154 | — | [4 2026-06-05] |
| 2026-06-04 | Ortwein Sara N | grant | 4,616 | — | [4 2026-06-05] |
| 2026-06-04 | Mack Roszell Iii | grant | 5,308 | — | [4 2026-06-05] |
| 2026-06-04 | Tanzberger Eric D | grant | 5,308 | — | [4 2026-06-05] |
| 2026-06-04 | Nixon Ronald T | grant | 4,154 | — | [4 2026-06-05] |
| 2026-06-04 | Desutter Robert Andrew | grant | 5,539 | — | [4 2026-06-05] |
| 2026-06-04 | Major Eric D | grant | 4,846 | — | [4 2026-06-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Shareholder vote results; Other events |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-08-11 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-07-31 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-29 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-06-09 | 8-K | Shareholder vote results |
| 2026-06-04 | 8-K | Material agreement terminated |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-11 | 8-K | Results of operations |
| 2026-04-17 | DEF 14A | Proxy statement |
| 2026-04-14 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $SMTI
Email me when Sanara MedTech Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.